NCT00004078View on ClinicalTrials.gov

Irinotecan in Treating Children With Refractory Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

October 31, 2007

Conditions
Childhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood Infratentorial EpendymomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaPreviously Treated Childhood RhabdomyosarcomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent OsteosarcomaUnspecified Childhood Solid Tumor, Protocol Specific
Interventions
DRUG

irinotecan hydrochloride

Given IV

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK